PMV Pharmaceuticals, Inc. (PMVP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.38
- As of
Kresmion compiles this page from PMVP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
PMV Pharmaceuticals, Inc. (PMVP): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-05.
See the full PMVP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PMVP on one page. Preview it with sample data, then open it live with a free account.
Preview the PMVP dossierActive events for PMVP
- mediumEarnings above estimates
Q2-2026: Beat consensus by 14.0%, EPS $-0.34 vs $-0.3953 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 60% of PMVP (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +71% to PMVP (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +167% to PMVP (2026Q1)
- mediumEarnings above estimates
Q4-2025: Beat consensus by 17.7% - EPS $-0.34 vs $-0.4131 estimate
FREE, NO ACCOUNT
Every event on PMVP, as it fires
You are seeing 5 of 6 events recorded on PMVP since 2026-05-26.
The five above landed across 4 days. The other 1 were recorded on those same days. 3 of the 6 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PMVP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 69353Y103 · 2026Q2 | $2.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 69353Y103 · 2026Q2 | $63K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PMVP
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PMVP against its peers
PMVP's return on equity of -74.2% ranks in the 62nd percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.
| Metric | PMVP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 5.8M | n/a | 12 |
| Operating margin | n/a | -251.6% | n/a | 12 |
| Net margin | n/a | -267.1% | n/a | 13 |
| Return on equity | -74.2% | -95.0% | 62 | 16 |
Peers (22): SMNR, ATRA, TNYA, PLYX, RLYB, KZIA, INO, MIST, GNLX, NRXS, COYA, PTHS, CRBP, EQ, NTHI, PDSB, ACRV, ICCC, OKYO, CLLS, TVGN, CRDF. Left out: TNXP (no annual filing), CNXU (no annual filing), TELO (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (PMVP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PMVP on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PMVP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.